MedPath

ymphatic Venous Anastomosis for secondary lymphedema -Randamized Control Trial

Not Applicable
Conditions
Secondary lymphedema
Registration Number
JPRN-UMIN000031462
Lead Sponsor
JR tokyo general Hospital BETHEL MINAMI-Shinjuku clinic Mihara Interanal medicine clinic
Brief Summary

Analysis First, I will describe the results of the FAS analysis. The incidence of cellulitis over 6 months, the primary outcome, was -0.57 in the LVA group and -0.21 in the CDT group. The difference was -0.35 times (95% confidence interval: -0.62 to -0.09), and Welch's t-test showed that the cellulitis prevention effect was significantly higher in the LVA group (p = 0.010).

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
336
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who conflict with the following criteria shall not be included in this study. 1) Patients who can be expected to have a postoperative follow-up period of less than 6 months at JR Tokyo General Hospital, Bethel Minami Shinjuku Clinic, Medical Corporation Mihara Internal Medicine 2) Patients with complication of edema due to heart failure, renal failure, etc. 3) Cases judged inappropriate by the doctor sharing test

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluate based on the change in the number of times of cellulitis. In the LVA group, the number of times of cellulitis inflammation during 24 weeks before the start of the intervention and 24 weeks after the start of the intervention is compared. In the conservative therapy group, we compare the number of times of cellulitis in 24 weeks before the allocation date and 24 weeks after the allocation date. Huigong weeping inflammation is defined as having inflammatory findings such as redness and heat sensation on the affected limb and having a fever of 38.5 degrees or more.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath